Connect with us

Headlines

Allergan Sued Over Dry Eye Drug Marketing Tactics

mm

Published

on

It’s accused of trying to block out competition.

Shire Plc has filed a lawsuit accusing Allergan Plc of antitrust violations in connection with Allergan’s dry eye medication Restasis, Reuters reports.

The lawsuit claims that Allergan’s goal was to maintain Restasis’ position in Medicare prescription drug plans. Allergan sought to prevent the Shire drug Xiidra from getting a foothold in that market, according to the suit.

Shire claims that Allergan used “bundled discounts, exclusive dealing, coercion and interference to unlawfully ‘block’ Shire from competing with it.”

Allergan wants to “maintain its monopoly in the Part D market at all costs,” according to Shire.

Advertisement

An Allergan spokesman told Reuters the lawsuit was without merit.

The suit was filed in U.S. District Court in New Jersey.

Read more at Reuters

Advertisement

SPONSORED VIDEO

SPONSORED BY ESSILOR

Introducing EssilorLuxottica 360

A new program powered by Essilor, Luxottica and EyeMed that is designed to help your practice improve traffic, visibility and patient experience while maximizing profitability. Learn More at 360.EssilorLuxottica.com

Promoted Headlines

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular